Answers are grounded in this paper and cite their sources.
Background Gastroesophageal adenocarcinoma (GEA) remains a major global health burden. For metastatic human epidermal growth factor receptor 2 (HER2)/programmed death-ligand 1 (PD-L1)-positive disease, first-line treatment includes platinum/fluoropyrimidine chemotherapy with trastuzumab and pembrolizumab. In the phase III HERIZON-GEA-01 trial, zanidatamab, a HER2-directed bispecific antibody, demonstrated improved progression-free survival (PFS) and overall survival (OS) combined with chemotherapy and tislelizumab compared with chemotherapy and trastuzumab. HERIZON did not study FOLFOX chemotherapy or pembrolizumab, commonly used treatments in clinical practice. Thus, the ZANGEA trial is evaluating zanidatamab plus modified FOLFOX (mFOLFOX) and pembrolizumab as first-line therapy for HER2/PD-L1-positive GEA. Patients and methods ZANGEA is a prospective, open-label, single-arm, multinational, phase II trial with a translational research program enrolling ∼80 patients with untreated metastatic HER2/PD-L1-positive GEA. Patients receive zanidatamab in combination with mFOLFOX and pembrolizumab. The primary endpoint is the 12-month PFS rate. Secondary endpoints include objective response rate, disease control rate, duration of response, PFS, OS, safety, tolerability, health-related quality of life, and translational correlates. Biomarker analyses include blood-based immune markers, neutrophil-to-lymphocyte ratio, dietary patterns, and microbiota (metabolite) composition associated with response or adverse events, particularly diarrhea. Results Recruitment started in January 2026. As of September 2026, 19 patients have been enrolled and completion of accrual is expected by the end of 2027. No results are currently available. Conclusion ZANGEA will assess the clinical activity and safety of zanidatamab plus mFOLFOX and pembrolizumab in first-line HER2/PD-L1-positive metastatic GEA and may identify biomarkers to guide patient selection and toxicity management.
No takes yet. Share an insight, caveat, or question.
Gorgulho et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: